cnbc.com / .cnbc-com-health-care / Page 2

Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.

The order builds on the Trump administration's efforts to reshape the childhood shot schedule under HHS Secretary RFK Jr., a longtime a vaccine skeptic.

Genetic testing is helping doctors identify rare diseases earlier, opening the door to treatment options before symptoms appear.

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

"The cancer has spread, is metastasized into his bones and further. It's very painful. It's very debilitating in many respects," Hunter Biden said.

Traffic to salad chains has fallen as consumers avoid greens due to the ongoing cyclospora outbreaks across the U.S.

CNBC's Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities.

"On the advice of my doctors, I'll maintain an intensive regimen of physical therapy from home during the state work period," the 84-year-old McConnell said.

CAMP4 is preparing a Phase 1/2 trial of an experimental SYNGAP1 therapy, marking a major milestone for patients with the rare disease.

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.